July 8th, 2008
A molecule called STF-62247 has been discovered by Stanford University School of Medicine researchers to be toxic against kidney cancer cells but is generally harmless to most other cells in the human body.
According to Amato Giaccia, PhD, professor and director of radiation oncology and radiation biology at the medical school:
“You now have a potential means […]
By Gloria Gamat -- 0 comments
March 11th, 2008
It just sucks when I cannot get online without going out of the house. But that’s exactly what happened to me in the last 3 days.
Suddenly, my crappy PC is the most beautiful work station on the face of the earth! Ha ha ha. ;-)
Anyways, I just wanna list those important stuff that I missed […]
By Gloria Gamat -- 0 comments
January 25th, 2008
According to a study that appeared online in the January 22 issue of Lancet Oncology, patients taking Nexavar® (sorafenib) need to be carefully monitored and treated.
In clinical testing, Nexavar improved overall survival by 44 percent among people with HCC. Median overall survival was 10.7 months among those treated with the drug, versus 7.9 months among […]
By Gloria Gamat -- 0 comments
August 1st, 2007
Compared to either agent alone, the combination of interferon alpha and sorafenib has been found to work better for patients with renal cell carcinoma –the common form of kidney cancer.
Such were the findings of a pilot study led by Duke University Comprehensive Cancer Center researchers.
According to Jared Gollob, M.D., an oncologist at Duke and lead […]
By Gloria Gamat -- 0 comments
June 5th, 2007
Presented Monday at the annual meeting of the American Society of Clinical Oncology, the cure for liver cancer in Sorafenib.
Phase III clinical trial data of this miracle pill revealed that chances of survival from final stage liver cancer is increased by 44% or about three months life extension.
Final stage liver cancer is deadly and currently […]
By Gloria Gamat -- 14 comments
June 1st, 2007
Wyeth Pharmaceuticals’ new kidney cancer drug Torisel™ (temsirolimus) has recently been approved by the FDA for the treatment of renal cell carcinoma - a type of advanced kidney cancer.
Torisel™ is an enzyme inhibitor (mTOR inhibitor to be exact) whose FDA approval came following results of prolonged survival in renal cell carcinoma patients.
According to Dr. Steven […]
By Gloria Gamat -- 1 comment
May 17th, 2007
Regardless of the type of alcoholic beverage (beer wine, liquor) - in both men and women - drinking at least an average of one alcoholic beverage a day was found associated with a 30% reduction in renal cancer risk.
Such is the result of an analysis of 12 prospective studies of alcohol consumption among renal cancer […]
By Gloria Gamat -- 0 comments
March 13th, 2007
Cell renal carcinoma is the most common and aggressive type of renal tumor or kidney cancer.
Imaging with Positron Emission Tomography (PET) using a radiolabeled monoclonal antibody G250 (originally developed as a potential therapeutic agent) can accurately identify cell renal carcinoma that needs surgery.
This was based on findings of a new study done by researchers at […]
By Gloria Gamat -- 0 comments
October 25th, 2006
According to a new study published online October 20, 2006 in the International Journal of Cancer (the official journal of the International Union Against Cancer or UICC), there is a significant link between high bread consumption and renal cell carcinoma and that eating a lot of pasta and rice may also raise the risk, while eating […]
By Gloria Gamat -- 0 comments
September 8th, 2006
Removing the entire kidney is the gold standard for 40 years in the treatment of a single, small tumor in the kidney.
A retrospective study appearing in the September issue of The Lancet Oncology suggests that such practice needs to be re-evaluated.
Urologists at the Memorial Sloan-Kettering Cancer Center (MSKCC) and their colleagues reported that with advances in […]
By Gloria Gamat -- 1 comment
Recent Comments